|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:age
|
6 months and older
|
|
gptkbp:alsoKnownAs
|
gptkb:Comirnaty
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
2020
2 December 2020
|
|
gptkbp:boosterFormulation
|
bivalent (Omicron-adapted)
|
|
gptkbp:boosters
|
yes
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
|
|
gptkbp:contains
|
gptkb:plastic
gptkb:disodium_hydrogen_phosphate
sodium chloride
potassium chloride
sucrose
lipid nanoparticles
potassium dihydrogen phosphate
water for injection
nucleoside-modified mRNA
|
|
gptkbp:countryOfOrigin
|
gptkb:United_Kingdom
|
|
gptkbp:developedBy
|
gptkb:Pfizer
gptkb:BioNTech
|
|
gptkbp:distribution
|
global
|
|
gptkbp:effect
|
over 90% against symptomatic COVID-19 (original strain)
|
|
gptkbp:emergencyServices
|
granted in multiple countries
|
|
gptkbp:form
|
suspension for injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BNT162b2
|
|
gptkbp:indication
|
prevention of COVID-19
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
gptkb:BioNTech
|
|
gptkbp:numberOfDoses
|
2
|
|
gptkbp:patent
|
gptkb:Pfizer
gptkb:BioNTech
|
|
gptkbp:pregnancyCategory
|
consult healthcare provider
|
|
gptkbp:routeOfAdministration
|
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
chills
injection site pain
anaphylaxis (rare)
myocarditis (rare)
|
|
gptkbp:storage
|
-70°C
|
|
gptkbp:target
|
gptkb:SARS-CoV-2_spike_protein
|
|
gptkbp:technology
|
gptkb:gene
|
|
gptkbp:vaccineType
|
vaccine
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:BioNTech
gptkb:Comirnaty
gptkb:Pfizer-BioNTech
|
|
gptkbp:bfsLayer
|
5
|